Since the beginning of the year, it seems, all eyes have been on the second half of 2021 as medtech companies were still grappling with a lot of uncertainty heading into 2021. Now that we're well into the second quarter, here are some key takeaways from first-quarter earnings calls from a handful of medtech companies that were most impacted by COVID-19 disruptions and lower procedure volumes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,